Prices for new US drugs doubled in 4 years as focus on rare disease grows
By Deena Beasley (Reuters) -U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...
Read moreDetailsTag: rare diseases
Exclusive-Germany’s Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say
By Sabrina Valle and Patricia Weiss NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, is in ...
Read moreDetails
